Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Short Interest Update

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totaling 780,056 shares, a growth of 12.4% from the March 31st total of 693,909 shares. Currently, 3.3% of the shares of the company are short sold. Based on an average daily volume of 213,098 shares, the short-interest ratio is currently 3.7 days.

Whitehawk Therapeutics Stock Down 0.7%

Shares of WHWK opened at $4.01 on Friday. Whitehawk Therapeutics has a 12-month low of $1.44 and a 12-month high of $4.48. The firm has a market capitalization of $189.26 million, a price-to-earnings ratio of 8.53 and a beta of 0.57. The stock’s 50-day moving average price is $3.68 and its 200 day moving average price is $2.91.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.21. Equities research analysts expect that Whitehawk Therapeutics will post -1.43 EPS for the current year.

Insider Transactions at Whitehawk Therapeutics

In other news, insider Bryan Ball sold 92,460 shares of Whitehawk Therapeutics stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $3.64, for a total value of $336,554.40. Following the transaction, the insider directly owned 397,106 shares in the company, valued at approximately $1,445,465.84. The trade was a 18.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David James Lennon sold 102,395 shares of Whitehawk Therapeutics stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $3.51, for a total value of $359,406.45. Following the completion of the transaction, the chief executive officer owned 691,154 shares in the company, valued at $2,425,950.54. The trade was a 12.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 705,358 shares of company stock worth $2,584,564. Company insiders own 49.90% of the company’s stock.

Institutional Investors Weigh In On Whitehawk Therapeutics

A number of institutional investors have recently added to or reduced their stakes in WHWK. Orbimed Advisors LLC acquired a new stake in Whitehawk Therapeutics during the third quarter valued at approximately $7,915,000. Suvretta Capital Management LLC acquired a new stake in Whitehawk Therapeutics during the third quarter valued at approximately $7,030,000. Acuta Capital Partners LLC acquired a new stake in Whitehawk Therapeutics during the third quarter valued at approximately $6,480,000. Avoro Capital Advisors LLC acquired a new stake in Whitehawk Therapeutics during the third quarter valued at approximately $5,414,000. Finally, KVP Capital Advisors LP acquired a new stake in Whitehawk Therapeutics during the fourth quarter valued at approximately $5,242,000. 52.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on WHWK. Citizens Jmp began coverage on Whitehawk Therapeutics in a research note on Thursday, April 16th. They set a “market outperform” rating and a $8.00 price target on the stock. Wall Street Zen lowered Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Oppenheimer began coverage on Whitehawk Therapeutics in a research note on Thursday, February 5th. They set an “outperform” rating and a $6.00 price target on the stock. Citigroup began coverage on Whitehawk Therapeutics in a research note on Thursday, April 16th. They set an “outperform” rating on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.